Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
9 studies found for:    "Bowens disease"
Show Display Options
Download search resultsDownload the search results for:
"Bowens disease" (9 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Enrolling by invitation Topical Imiquimod for Bowen's Disease of the Head and Neck
Condition: Bowens Disease
Intervention: Drug: Imiquimod
2 Completed Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease
Condition: Bowen's Disease
Interventions: Drug: Er:YAG AFL-PDT;   Drug: MAL-PDT
3 Terminated Trial of Excision Versus Photodynamic Therapy in the Treatment of Bowen's Disease
Condition: Bowen's Disease
Interventions: Procedure: excision;   Procedure: Photodynamic therapy
4 No longer available Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease
Conditions: Field Actinic Keratoses;   Basal Cell Carcinoma;   Bowen's Disease
Intervention: Drug: Metvix (methyl aminolevulinate)
5 Completed Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis
Conditions: Actinic Keratosis;   Bowen's Disease
Intervention: Drug: SR-T100 ® Gel
6 Unknown  Effects of Arsenic on Keratinocytes in a Skin Equivalent Model
Condition: Bowen Disease
Intervention: Procedure: foreskin from healthy adults for organotypic culture
7 Completed PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer
Conditions: Actinic Keratosis;   Warts;   Basal Cell Carcinoma;   Bowens Disease;   Squamous Cell Carcinoma
Intervention: Procedure: Photodynamic therapy with Metvix 160 mg/g cream
8 Completed Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ
Condition: Carcinoma, Squamous Cell
Intervention: Drug: PEP005
9 Completed Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
Conditions: Lymphoma;   Non-melanomatous Skin Cancer;   Precancerous Condition
Intervention: Drug: silicon phthalocyanine 4

Indicates status has not been verified in more than two years